Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
21 "Kyung Chul Moon"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Article image
Loss of aquaporin-1 expression is associated with worse clinical outcomes in clear cell renal cell carcinoma: an immunohistochemical study
Seokhyeon Lee, Bohyun Kim, Minsun Jung, Kyung Chul Moon
J Pathol Transl Med. 2023;57(4):232-237.   Published online July 11, 2023
DOI: https://doi.org/10.4132/jptm.2023.06.17
  • 1,935 View
  • 142 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDF
Background
Aquaporin (AQP) expression has been investigated in various malignant neoplasms, and the overexpression of AQP is related to poor prognosis in some malignancies. However, the expression of AQP protein in clear cell renal cell carcinoma (ccRCC) has not been extensively investigated by immunohistochemistry with large sample size.
Methods
We evaluated the AQP expression in 827 ccRCC with immunohistochemical staining in tissue microarray blocks and classified the cases into two categories, high and low expression.
Results
High expression of aquaporin-1 (AQP1) was found in 320 cases (38.7%), but aquaporin-3 was not expressed in ccRCC. High AQP1 expression was significantly related to younger age, low TNM stage, low World Health Organization/International Society of Urologic Pathology nuclear grade, and absence of distant metastasis. Furthermore, high AQP1 expression was also significantly associated with longer overall survival (OS; p<.001) and progression-specific survival (PFS; p<.001) and was an independent predictor of OS and PFS in ccRCC.
Conclusions
Our study revealed the prognostic significance of AQP1 protein expression in ccRCC. These findings could be applied to predict the prognosis of ccRCC.

Citations

Citations to this article as recorded by  
  • Serum Exosomal MiR-874 as a Potential Biomarker for Nonsmall Cell Lung Cancer Diagnosis and Prognosis
    Amal F. Gharib, Saad S. Al-Shehri, Abdulraheem Almalki, Ayman Alhazmi, Mamdouh Allahyani, Ahmed Alghamdi, Amani A. Alrehaili, Maha M. Bakhuraysah, Althobaiti Naif Saad M., Weal H. Elsawy
    Indian Journal of Medical and Paediatric Oncology.2024;[Epub]     CrossRef
Intraosseous Hibernoma: A Rare and Unique Intraosseous Lesion
Boram Song, Hye Jin Ryu, Cheol Lee, Kyung Chul Moon
J Pathol Transl Med. 2017;51(5):499-504.   Published online August 22, 2017
DOI: https://doi.org/10.4132/jptm.2017.07.28
  • 8,136 View
  • 128 Download
  • 11 Web of Science
  • 16 Crossref
AbstractAbstract PDF
Background
Hibernoma is a rare benign tumor of adults that is composed of multivacuolated adipocytes resembling brown fat cells. Hibernoma typically occurs in soft tissue, and intraosseous examples are very rare. Intraosseous hibernomas can radiologically mimic metastatic carcinoma and other tumorous conditions. Methods: To collect the intraosseous hibernomas, we searched the pathologic database and reviewed the hematoxylin and eosin (H&E)–stained slides of bone biopsy samples performed to differentiate radiologically abnormal bone lesions from 2006 to 2016. A total of six intraosseous hibernoma cases were collected, and clinical and radiological information was verified from electronic medical records. H&E slide review and immunohistochemical staining for CD68, pan-cytokeratin, and S-100 protein were performed. Results: Magnetic resonance imaging of intraosseous hibernomas showed low signal intensity with slightly hyperintense foci on T1 and intermediate to high signal intensity on T2 weighted images. Intraosseous hibernomas appeared as heterogeneous sclerotic lesions with trabecular thickening on computed tomography scans and revealed mild hypermetabolism on positron emission tomography scans. Histopathologically, the bone marrow space was replaced by sheets of multivacuolated, foamy adipocytes resembling brown fat cells, without destruction of bone trabeculae. In immunohistochemical analysis, the tumor cells were negative for CD68 and pan-cytokeratin and positive for S-100 protein. Conclusions: Intraosseous hibernoma is very rare. This tumor can be overlooked due to its rarity and resemblance to bone marrow fat. Pathologists need to be aware of this entity to avoid misdiagnosis of this rare lesion.

Citations

Citations to this article as recorded by  
  • A Rare Case of Large Lateral Chest Wall Hibernoma
    Lyubomir Gaydarski, Boycho Landzhov, Ivaylo Kamenov, Julian M Ananiev, Georgi P Georgiev
    Cureus.2024;[Epub]     CrossRef
  • Intraosseous hibernoma mimicking sclerotic bone metastasis—a case report
    Ali Shaikh, Adil Basha, George Ray, Justin A. Bishop, Avneesh Chhabra
    Skeletal Radiology.2024;[Epub]     CrossRef
  • Femoral hibernoma: unique intraosseous tumor
    Gökhan Tonkaz, Ertugrul Cakir, Mehmet Tonkaz, Demet Sengul
    Wiener klinische Wochenschrift.2024; 136(19-20): 581.     CrossRef
  • Unusual Imaging Findings of Epithelioid Hemangioma: Case Report of Single Intramedullary Sclerotic Bone Lesion
    Yun Chul Hwang, Tae Eun Kim, Jae Hyuck Yi
    Journal of the Korean Society of Radiology.2024; 85(5): 986.     CrossRef
  • Benign incidental do-not-touch bone lesions
    Nuttaya Pattamapaspong, Wilfred CG Peh
    The British Journal of Radiology.2023;[Epub]     CrossRef
  • Intraosseous hibernoma: clinicopathologic and imaging analysis of 18 cases
    Chiraag N Gangahar, Carina A Dehner, David P Wang, Behrang Amini, Travis Hillen, Christopher O'Conor, Sydney N Jennings, Kathleen Byrnes, Elizabeth A Montgomery, Bogdan A Czerniak, Julia A Bridge, Molly C Schroeder, Jack W Jennings, Wei‐Lien Wang, John S
    Histopathology.2023; 83(1): 40.     CrossRef
  • Intraosseous Hibernoma: A Rare Entity in Orthopedics With Peculiar Radiological Features
    Ramy Samargandi, Louis-Romée Le Nail, Gonzague de Pinieux, Matthias Tallegas, Elodie Miquelestorena-Standley
    Cureus.2023;[Epub]     CrossRef
  • Intraosseous hibernoma of the appendicular skeleton
    Salvatore Gitto, Thom Doeleman, Michiel A. J. van de Sande, Kirsten van Langevelde
    Skeletal Radiology.2022; 51(6): 1325.     CrossRef
  • Intraosseous hibernoma: Two case reports and a review of the literature
    Samantha N. Weiss, Ankit Mohla, Gord Guo Zhu, Christina Gutowski, Tae Won B Kim, Rohan Amin
    Radiology Case Reports.2022; 17(7): 2477.     CrossRef
  • Hibernoma of two contiguous vertebrae: uniqueness of a lesion already rare in itself
    Donato MASTRANTUONO, Domenico MARTORANO, Guido REGIS, Federica ARABIA, Alessandra LINARI, Federica SANTORO
    Journal of Radiological Review.2022;[Epub]     CrossRef
  • Primary extradural tumors of the spinal column
    Varun Arvind, Edin Nevzati, Maged Ghaly, Mansoor Nasim, Mazda Farshad, Roman Guggenberger, Daniel Sciubba, Alexander Spiessberger
    Journal of Craniovertebral Junction and Spine.2021; 12(4): 336.     CrossRef
  • Spinal Intraosseous Hibernoma: A Case Report and Review of Literature
    Mi-Kyung Um, Eugene Lee, Joon Woo Lee, Kyu Sang Lee, Yusuhn Kang, Joong Mo Ahn, Heung Sik Kang
    Journal of the Korean Society of Radiology.2020; 81(4): 965.     CrossRef
  • Intraosseous hibernoma: A metastatic mimicker to consider on the differential
    Allen Ko, Colin C. Rowell, James B. Vogler, Dmitri E. Samoilov
    Radiology Case Reports.2020; 15(12): 2677.     CrossRef
  • Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology
    Yu Jin Kim, Mingi Kim, Hyung Kyu Park, Dan Bi Yu, Kyungsoo Jung, Kyoung Song, Yoon-La Choi
    Laboratory Investigation.2019; 99(9): 1309.     CrossRef
  • Intraosseous Hibernoma: Five Cases and a Review of the Literature
    Francisco A. Myslicki, Andrew E. Rosenberg, Ivan Chaitowitz, Ty K. Subhawong
    Journal of Computer Assisted Tomography.2019; 43(5): 793.     CrossRef
  • Hibernoma Mimicking Atypical Lipomatous Tumor
    Youssef Al Hmada, Inga-Marie Schaefer, Christopher D.M. Fletcher
    American Journal of Surgical Pathology.2018; 42(7): 951.     CrossRef
Implication of PHF2 Expression in Clear Cell Renal Cell Carcinoma
Cheol Lee, Bohyun Kim, Boram Song, Kyung Chul Moon
J Pathol Transl Med. 2017;51(4):359-364.   Published online June 13, 2017
DOI: https://doi.org/10.4132/jptm.2017.03.16
  • 7,144 View
  • 166 Download
  • 9 Web of Science
  • 10 Crossref
AbstractAbstract PDF
Background
Clear cell renal cell carcinoma (CCRCC) is presumed to be associated with adipogenic differentiation. Histone modification is known to be important for adipogenesis, and the function of histone demethylase plant homeodomain finger 2 (PHF2) has been noted. In addition, PHF2 may act as a tumor suppressor via epigenetic regulation of p53 and is reported to be reduced in colon cancer and stomach cancer tissues. In this study, we examined PHF2 expression in CCRCC specimens by immunohistochemistry.
Methods
We studied 254 CCRCCs and 56 non-neoplastic renal tissues from patients who underwent radical or partial nephrectomy between 2000 and 2003 at the Seoul National University Hospital. Tissue microarray blocks were prepared, and immunohistochemical staining for PHF2 was performed.
Results
Among 254 CCRCC cases, 150 cases (59.1%) showed high expression and 104 cases (40.1%) showed low expression. High expression of PHF2 was significantly correlated with a low Fuhrman nuclear grade (p < .001), smaller tumor size (p < .001), low overall stage (p = .003), longer cancer-specific survival (p = .002), and progression-free survival (p < .001) of the patients. However, it was not an independent prognostic factor in multivariate analysis adjusted for Fuhrman nuclear grade and overall stage.
Conclusions
Our study showed that low expression of PHF2 is associated with aggressiveness and poor prognosis of CCRCC.

Citations

Citations to this article as recorded by  
  • The role of histone methylation in renal cell cancer: an update
    Yanguang Hou, Yan Yuan, Yanze Li, Lei Wang, Juncheng Hu, Xiuheng Liu
    Molecular Biology Reports.2023; 50(3): 2735.     CrossRef
  • Phosphorylation of PHF2 by AMPK releases the repressive H3K9me2 and inhibits cancer metastasis
    Ying Dong, Hao Hu, Xuan Zhang, Yunkai Zhang, Xin Sun, Hanlin Wang, Weijuan Kan, Min-jia Tan, Hong Shi, Yi Zang, Jia Li
    Signal Transduction and Targeted Therapy.2023;[Epub]     CrossRef
  • HIF-1α-mediated augmentation of miRNA-18b-5p facilitates proliferation and metastasis in osteosarcoma through attenuation PHF2
    Peng Luo, Yan-dong Zhang, Feng He, Chang-jun Tong, Kai Liu, He Liu, Shi-zhuang Zhu, Jian-zhou Luo, Bing Yuan
    Scientific Reports.2022;[Epub]     CrossRef
  • Integration of meta-analysis and supervised machine learning for pattern recognition in breast cancer using epigenetic data
    Reza Panahi, Esmaeil Ebrahimie, Ali Niazi, Alireza Afsharifar
    Informatics in Medicine Unlocked.2021; 24: 100629.     CrossRef
  • PHF2 regulates homology-directed DNA repair by controlling the resection of DNA double strand breaks
    Ignacio Alonso-de Vega, Maria Cristina Paz-Cabrera, Magdalena B Rother, Wouter W Wiegant, Cintia Checa-Rodríguez, Juan Ramón Hernández-Fernaud, Pablo Huertas, Raimundo Freire, Haico van Attikum, Veronique A J Smits
    Nucleic Acids Research.2020; 48(9): 4915.     CrossRef
  • Emerging of lysine demethylases (KDMs): From pathophysiological insights to novel therapeutic opportunities
    Sarder Arifuzzaman, Mst Reshma Khatun, Rabeya Khatun
    Biomedicine & Pharmacotherapy.2020; 129: 110392.     CrossRef
  • Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview
    Tyler S. McCann, Lays M. Sobral, Chelsea Self, Joseph Hsieh, Marybeth Sechler, Paul Jedlicka
    Expert Opinion on Therapeutic Targets.2019; 23(4): 267.     CrossRef
  • MiR-221 Promotes Hepatocellular Carcinoma Cells Migration via Targeting PHF2
    Yi Fu, Mingyan Liu, Fengxia Li, Li Qian, Ping Zhang, Fengwei Lv, Wenting Cheng, Ruixing Hou
    BioMed Research International.2019; 2019: 1.     CrossRef
  • PHF2 histone demethylase prevents DNA damage and genome instability by controlling cell cycle progression of neural progenitors
    Stella Pappa, Natalia Padilla, Simona Iacobucci, Marta Vicioso, Elena Álvarez de la Campa, Claudia Navarro, Elia Marcos, Xavier de la Cruz, Marian A. Martínez-Balbás
    Proceedings of the National Academy of Sciences.2019; 116(39): 19464.     CrossRef
  • Plant homeodomain finger protein 2 as a novel IKAROS target in acute lymphoblastic leukemia
    Zheng Ge, Yan Gu, Qi Han, Justin Sloane, Qinyu Ge, Goufeng Gao, Jinlong Ma, Huihui Song, Jiaojiao Hu, Baoan Chen, Sinisa Dovat, Chunhua Song
    Epigenomics.2018; 10(1): 59.     CrossRef
Case Studies
Perivascular Epithelioid Cell Tumor in the Stomach
Sun Ah Shin, Jiwoon Choi, Kyung Chul Moon, Woo Ho Kim
J Pathol Transl Med. 2017;51(4):428-432.   Published online April 4, 2017
DOI: https://doi.org/10.4132/jptm.2016.09.16
  • 7,737 View
  • 140 Download
  • 4 Web of Science
  • 3 Crossref
AbstractAbstract PDF
Perivascular epithelioid cell tumors or PEComas can arise in any location in the body. However, a limited number of cases of gastric PEComa have been reported. We present two cases of gastric PEComas. The first case involved a 62-year-old woman who presented with a 4.2 cm gastric subepithelial mass in the prepyloric antrum, and the second case involved a 67-year-old man with a 5.0 cm mass slightly below the gastroesophageal junction. Microscopic examination revealed that both tumors were composed of perivascular epithelioid cells that were immunoreactive for melanocytic and smooth muscle markers. Prior to surgery, the clinical impression of both tumors was gastrointestinal stromal tumor (GIST), and the second case was erroneously diagnosed as GIST even after microscopic examination. Although gastric PEComa is a very rare neoplasm, it should be considered in the differential diagnosis of gastric submucosal lesions.

Citations

Citations to this article as recorded by  
  • Unusual paediatric sigmoid perivascular epithelioid cell tumour with regional lymph node metastasis treated using gemcitabine and docetaxel: a case report and literature review
    Hsiu-Chung Cheng, Chia-Yu Kuo, Ching-Wen Huang, Hsiang-Hung Shih, Chih-Hung Lin, Jaw-Yuan Wang
    Journal of International Medical Research.2021;[Epub]     CrossRef
  • Gastric Perivascular Epithelioid Cell Tumor (PEComa)
    Jinghong Xu, Yu Yan, Xueping Xiang, Peter Jiang, Xiangrong Hu, Wenjun Yang
    American Journal of Clinical Pathology.2019; 152(2): 221.     CrossRef
  • Robotic wedge resection of a rare gastric perivascular epithelioid cell tumor: A case report
    Alessandra Marano, Francesca Maione, Yanghee Woo, Luca Pellegrino, Paolo Geretto, Diego Sasia, Mirella Fortunato, Giulio Fraternali Orcioni, Roberto Priotto, Renato Fasoli, Felice Borghi
    World Journal of Clinical Cases.2019; 7(23): 4011.     CrossRef
Mucinous Cystadenoma of the Testis: A Case Report with Immunohistochemical Findings
Gilhyang Kim, Dohee Kwon, Hee Young Na, Sehui Kim, Kyung Chul Moon
J Pathol Transl Med. 2017;51(2):180-184.   Published online February 13, 2017
DOI: https://doi.org/10.4132/jptm.2016.08.30
  • 8,069 View
  • 122 Download
  • 5 Web of Science
  • 8 Crossref
AbstractAbstract PDF
Mucinous cystadenoma of the testis is a very rare tumor. Herein, we report a case of mucinous cystadenoma arising in the testis of a 61-year-old man, along with a literature review. Computed tomography showed a 2.5-cm-sized poorly enhancing cystic mass. Grossly, the tumor was a unilocular cystic mass filled with mucinous material and confined to the testicular parenchyma. Histologically, the cyst had a fibrotic wall lined by mucinous columnar epithelium without atypia. Immunohistochemical staining was positive for cytokeratin 20 and CDX2, as well as focally positive for cytokeratin 7. The pathologic diagnosis was mucinous cystadenoma.

Citations

Citations to this article as recorded by  
  • Review of Paratesticular Appendageal Tumors, Morphology, Immunohistochemistry, and Recent Molecular Advances
    Mathew Vega, Muhammad T. Idrees
    Surgical Pathology Clinics.2024;[Epub]     CrossRef
  • Cistoadenoma Mucinoso Paratesticular: Caso Interesante en el Instituto Guatemalteco de Seguridad Social
    Edgar Estuardo González López, Carlos Gonzalo Estrada Pazos
    Revista Guatemalteca de Urología.2023; 10(2): 16.     CrossRef
  • Primary borderline mucinous tumor of the testis with postoperative metastasis: A rare case report
    Yingyu Shi, Ling Song, Yan Luo
    Radiology Case Reports.2023; 18(9): 3203.     CrossRef
  • Case report: Misdiagnosis of primary mucinous cystadenoma of the testicle by ultrasound
    Linlin Zhang, Jianyuan Xuan, Manxi Li, Mei Zhang, Yu Song, Ziang Pan, Bo Fan, Lin Lu, Hongyan Zhou, Yang Li
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Primary Borderline Mucinous Testicular Tumor: A Case Report and Literature Review
    Changjuan Hao, Chunsong Kang, Xiaoyan Kang, Zhuanzhuan Yu, Tingting Li, Jiping Xue
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Ovarian-type Tumors (Mullerian Tumors) of the Testis: Clinicopathologic Findings with Recent Advances
    Michelle S Lin, Alberto G Ayala, Jae Y Ro
    annals of urologic oncology.2019; : 1.     CrossRef
  • Borderline Mucinous Testicular Tumour: Diagnostic and Management difficulties
    Krishan Pratap, Marlon Perera, Frances Malczewski, Rachel Esler
    BMJ Case Reports.2018; : bcr-2017-223787.     CrossRef
  • Mucinous tumor arising in a giant sacrococcygeal teratoma
    Fengtian Zhang, Xiaolong Yu, Jin Zeng, Min Dai
    Medicine.2017; 96(47): e8759.     CrossRef
Original Article
Article image
Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
Gilhyang Kim, Yul Ri Chung, Bohyun Kim, Boram Song, Kyung Chul Moon
J Pathol Transl Med. 2016;50(6):436-441.   Published online October 10, 2016
DOI: https://doi.org/10.4132/jptm.2016.07.12
  • 8,271 View
  • 116 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDF
Background
Human epidermal growth factor receptor 2 (HER2) is one of the known oncogenes in urothelial carcinoma. However, the association between HER2 and the prognosis of upper urinary tract urothelial carcinoma (UUTUC) has not yet been fully clarified. The aim of this study was to evaluate HER2 expression using the United States Food and Drug Administration (FDA) criteria and American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria and compare their prognostic significance in UUTUC.
Methods
HER2 expression was evaluated in 144 cases of UUTUC by immunohistochemistry (IHC) using tissue microarrays. We separately analyzed HER2 expression using the FDA and ASCO/CAP criteria. The IHC results were categorized into low (0, 1+) and high (2+, 3+) groups.
Results
Using the FDA criteria, 94 cases were negative, 38 cases were 1+, nine cases were 2+, and three cases were 3+. Using the ASCO/CAP criteria, 94 cases were negative, 34 cases were 1+, 13 cases were 2+, and three cases were 3+. Four cases showing 2+ according to the ASCO/CAP criteria were reclassified as 1+ by the FDA criteria. High HER2 expression by both the FDA criteria and ASCO/CAP criteria was significantly associated with International Society of Urological Pathology high grade (p = .001 and p < .001). The high HER2 expression group classified with the FDA criteria showed significantly shorter cancer-specific survival (p = .004), but the HER2 high and low expression groups classified with the ASCO/CAP criteria did not show significant differences (p = .161) in cancer-specific survival.
Conclusions
HER2 high expression groups were significantly associated with shorter cancer-specific survival, and our study revealed that the FDA criteria are more suitable for determining HER2 expression in UUTUC.

Citations

Citations to this article as recorded by  
  • A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients
    Jianjun Ye, Xinyang Liao, Yu Qiu, Qiang Wei, Yige Bao
    Tumori Journal.2024; 110(1): 25.     CrossRef
  • ERBB2 Amplification as a Predictive and Prognostic Biomarker in Upper Tract Urothelial Carcinoma
    Annette Zimpfer, Said Kdimati, Melanie Mosig, Henrik Rudolf, Heike Zettl, Andreas Erbersdobler, Oliver W. Hakenberg, Matthias Maruschke, Björn Schneider
    Cancers.2023; 15(9): 2414.     CrossRef
  • Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers
    Hiroshi Fukushima, Baris Turkbey, Peter A. Pinto, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
    Cancers.2022; 14(12): 2996.     CrossRef
  • Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication
    Manuela Costantini, Carla Azzurra Amoreo, Liborio Torregrossa, Greta Alì, Enrico Munari, Carmen Jeronimo, Rui Henrique, Sara Petronilho, Umberto Capitanio, Roberta Lucianò, Nazareno Suardi, Maria Teresa Landi, Umberto Anceschi, Aldo Brassetti, Vito Michel
    Cancers.2020; 12(11): 3345.     CrossRef
Brief Case Report
Squamous Cell Carcinoma of the Seminal Vesicle from Zinner Syndrome: A Case Report and Review of Literature
Younghoon Kim, Hae Woon Baek, Eunoh Choi, Kyung Chul Moon
J Pathol Transl Med. 2015;49(1):85-88.   Published online January 15, 2015
DOI: https://doi.org/10.4132/jptm.2014.10.28
  • 10,563 View
  • 76 Download
  • 6 Web of Science
  • 7 Crossref
PDF

Citations

Citations to this article as recorded by  
  • Zinner syndrome in pediatric patients: rare disease leading to challenging management
    Ottavio Adorisio, Cinzia Orazi, Lorenzo Maria Gregori, Francesco De Peppo, Massimiliano Silveri
    Frontiers in Pediatrics.2024;[Epub]     CrossRef
  • Zinner syndrome: a rare diagnosis in infancy
    Joanne Michelle Oida Rose, Ravi Banthia, Zain Tamboli, Hira Lal
    BMJ Case Reports.2022; 15(5): e248558.     CrossRef
  • Classifying seminal vesicle cysts in the diagnosis and treatment of Zinner syndrome: A report of six cases and review of available literature
    Zhengwu Tan, Bing Li, Lan Zhang, Ping Han, Haitao Huang, Andrew Taylor, Xin Li
    Andrologia.2020;[Epub]     CrossRef
  • Incidental imaging findings suggesting Zinner syndrome in a young patient with pulmonary embolism: A case report
    Benedikt Hergan, Franz A. Fellner, Kaveh Akbari
    Radiology Case Reports.2020; 15(4): 437.     CrossRef
  • Ectopic ureter associated with Zinner’s syndrome in a kidney recipient: case report and literature review
    Korhan Tuncer, Gizem Kilinc, Ismail Sert, Goksever Akpinar, Cem Tugmen
    Revista da Associação Médica Brasileira.2020; 66(5): 692.     CrossRef
  • Zinner’s Syndrome: A Rare Diagnosis of Dysuria Based on Imaging
    Ahmed Ibrahimi, Abdelmoughit Hosni, Idriss Ziani, Fatima Zahra Laamrani, Hachem El Sayegh, Laila Jroundi, Lounis Benslimane, Yassine Nouini, Apul Goel
    Case Reports in Urology.2020; 2020: 1.     CrossRef
  • Primary squamous cell carcinoma of the seminal vesicle
    Lu Fang, Qian Hong, Lei Chen, Yi Wang, Liang-Kuan Bi, Dong-Dong Xie, De-Xin Yu
    Medicine.2019; 98(12): e14788.     CrossRef
Original Articles
Transglutaminase 2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma
Min Jee Park, Hae Woon Baek, Ye-Young Rhee, Cheol Lee, Jeong Whan Park, Hwal Woong Kim, Kyung Chul Moon
J Pathol Transl Med. 2015;49(1):37-43.   Published online January 15, 2015
DOI: https://doi.org/10.4132/jptm.2014.10.25
  • 9,103 View
  • 79 Download
  • 15 Web of Science
  • 17 Crossref
AbstractAbstract PDF
Background
A few recent studies have demonstrated a possible role of transglutaminase 2 (TG2) in tumorigenesis or progression of renal cell carcinoma (RCC). The aim of this study was to examine TG2 expression and its clinicopathologic significance in a large number of human clear cell RCCs (CCRCCs). Methods: We analyzed 638 CCRCC patients who underwent partial or radical nephrectomy between 1995 and 2005. The expression of TG2 was determined by immunohistochemistry and categorized into four groups, according to staining intensity: negative (0), mild (1+), moderate (2+), and strong (3+). Results: TG2 staining intensity was negative in 8.5% of CCRCC (n=54), 1+ in 32.6% (n=208), 2+ in 50.5% (n=322), and 3+ in 8.5% (n=54). Strong TG2 expression was correlated with high Fuhrman nuclear grade (p=.011), high T category (p=.049), metastasis (p=.043) and male sex (p<.001) but not with N category.The survival analysis showed a significant association between strong TG2 expression and worse overall and cancer-specific survival (p=.027 and p=.010, respectively). On multivariate analysis, strong TG2 expression was a marginally significant prognostic indicator for Fuhrman nuclear grade and TNM staging (p=.054). Conclusions: Our study is the first to demonstrate the clinicopathologic significance of TG2 expression in a large number of human CCRCC samples. Strong TG2 expression was associated with high nuclear grade and poor prognosis.

Citations

Citations to this article as recorded by  
  • Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma
    Ga-Ram Kim, Joon Hee Kang, Hyeon Joo Kim, Eunji Im, Jinsu Bae, Woo Sun Kwon, Sun Young Rha, Hyun Cheol Chung, Eun Yi Cho, Soo-Youl Kim, Yong-Chul Kim
    Bioorganic Chemistry.2024; 143: 107061.     CrossRef
  • Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target
    Patrizia Malkomes, Ilaria Lunger, Elsie Oppermann, Johannes Lorenz, Sara Fatima Faqar-Uz-Zaman, Jiaoyan Han, Sabrina Bothur, Paul Ziegler, Katrin Bankov, Peter Wild, Wolf Otto Bechstein, Michael A. Rieger
    Cancer Gene Therapy.2023; 30(10): 1346.     CrossRef
  • Transglutaminase Type 2-MITF axis regulates phenotype switching in skin cutaneous melanoma
    Silvia Muccioli, Valentina Brillo, Tatiana Varanita, Federica Rossin, Elisabetta Zaltron, Angelo Velle, Giorgia Alessio, Beatrice Angi, Filippo Severin, Anna Tosi, Manuela D’Eletto, Luca Occhigrossi, Laura Falasca, Vanessa Checchetto, Roberto Ciaccio, Ame
    Cell Death & Disease.2023;[Epub]     CrossRef
  • The role of transglutaminase 2 in regulation of the balance between autophagy and apoptosis in tumor cells
    Yu. A. Gnennaya, O.  M. Semenov, N. A. Barlev
    Advances in Molecular Oncology.2023; 10(4): 31.     CrossRef
  • Application of a Fluorescence Anisotropy-Based Assay to Quantify Transglutaminase 2 Activity in Cell Lysates
    Sandra Hauser, Paul Sommerfeld, Johanna Wodtke, Christoph Hauser, Paul Schlitterlau, Jens Pietzsch, Reik Löser, Markus Pietsch, Robert Wodtke
    International Journal of Molecular Sciences.2022; 23(9): 4475.     CrossRef
  • The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour Microenvironment
    Robert Tempest, Sonia Guarnerio, Rawan Maani, Jamie Cooper, Nicholas Peake
    Cancers.2021; 13(11): 2788.     CrossRef
  • A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2
    Soo-Youl Kim, Jeffrey W. Keillor
    International Journal of Molecular Sciences.2020; 21(7): 2493.     CrossRef
  • Evaluation of nuclear NF-κB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors
    Alan A. Azambuja, Paula Engroff, Bruna T. Silva, Roberta C. S. Zorzetti, Fernanda B. Morrone
    International braz j urol.2020; 46(3): 353.     CrossRef
  • Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma
    Seon-Hyeong Lee, Joon Hee Kang, Ji Sun Ha, Jae-Seon Lee, Su-Jin Oh, Hyun-Jung Choi, Jaewhan Song, Soo-Youl Kim
    International Journal of Molecular Sciences.2020; 21(14): 5042.     CrossRef
  • Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression
    Burge Ulukan, Ajna Bihorac, Tarik Sipahioglu, Robert Kiraly, Laszlo Fesus, Dilek Telci
    ACS Omega.2020; 5(43): 28273.     CrossRef
  • Transglutaminase 2: The Maestro of the Oncogenic Mediators in Renal Cell Carcinoma
    Ayca Ece Nezir, Burge Ulukan, Dilek Telci
    Medical Sciences.2019; 7(2): 24.     CrossRef
  • Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target
    Richard L. Eckert
    Molecular Carcinogenesis.2019; 58(6): 837.     CrossRef
  • Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus
    Nayeon Kim, Joon Hee Kang, Won-Kyu Lee, Seul-Gi Kim, Jae-Seon Lee, Seon-Hyeong Lee, Jong Bae Park, Kyung-Hee Kim, Young-Dae Gong, Kwang Yeon Hwang, Soo-Youl Kim
    Amino Acids.2018; 50(11): 1583.     CrossRef
  • Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition
    Seon-Hyeong Lee, Won-Kyu Lee, Nayeon Kim, Joon Hee Kang, Kyung-Hee Kim, Seul-Gi Kim, Jae-Seon Lee, Soohyun Lee, Jongkook Lee, Jungnam Joo, Woo Sun Kwon, Sun Young Rha, Soo-Youl Kim
    Cancers.2018; 10(11): 455.     CrossRef
  • Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma
    Yesim Bagatur, Ayca Zeynep Ilter Akulke, Ajna Bihorac, Merve Erdem, Dilek Telci
    Cell Adhesion & Migration.2017; : 1.     CrossRef
  • Characterization of clear cell renal cell carcinoma by gene expression profiling
    Bryan J. Thibodeau, Matthew Fulton, Laura E. Fortier, Timothy J. Geddes, Barbara L. Pruetz, Samreen Ahmed, Amy Banes-Berceli, Ping L. Zhang, George D. Wilson, Jason Hafron
    Urologic Oncology: Seminars and Original Investigations.2016; 34(4): 168.e1.     CrossRef
  • Prognostic role of tissue transglutaminase 2 in colon carcinoma
    María Jesús Fernández-Aceñero, Sofía Torres, Irene Garcia-Palmero, Cristina Díaz del Arco, J. Ignacio Casal
    Virchows Archiv.2016; 469(6): 611.     CrossRef
ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients
Cheol Lee, Jeong Whan Park, Ja Hee Suh, Kyung Han Nam, Kyung Chul Moon
Korean J Pathol. 2013;47(5):452-457.   Published online October 25, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.5.452
  • 7,552 View
  • 66 Download
  • 28 Crossref
AbstractAbstract PDF
Background

Recently, there have been a few reports of renal cell carcinoma (RCC) cases with anaplastic lymphoma kinase (ALK) gene fusion. In this study, we screened consecutively resected RCCs from a single institution for ALK protein expression by immunohistochemistry, and then we performed fluorescence in situ hybridization to confirm the ALK gene alteration in ALK immunohistochemistry-positive cases.

Methods

We screened 829 RCCs by ALK immunohistochemistry, and performed fluorescence in situ hybridization analysis using ALK dual-color break-apart rearrangement probe. Histological review and additional immunohistochemistry analyses were done in positive cases.

Results

One ALK-positive case was found. Initial diagnosis of this case was papillary RCC type 2. This comprises 0.12% of all RCCs (1/829) and 1.9% of papillary RCCs (1/53). This patient was a 44-year-old male with RCC found during routine health check-up. He was alive without evidence of disease 12 years after surgery. The tumor showed a papillary and tubular pattern, and showed positivity for CD10 (focal), epithelial membrane antigen, cytokeratin 7, pan-cytokeratin, PAX-2, and vimentin.

Conclusions

We found the first RCC case with ALK gene rearrangement in Korean patients by ALK immunohistochemistry among 829 RCCs. This case showed similar histological and immunohistochemical features to those of previous adult cases with ALK rearrangement, and showed relatively good prognosis.

Citations

Citations to this article as recorded by  
  • ALK-Rearranged Renal Cell Carcinoma: A Multi-Institutional Study of 9 Cases With Expanding the Morphologic and Molecular Genetic Spectrum
    Ming Zhao, Xiaona Yin, Xiaoqun Yang, Hualei Gan, Ni Chen, Guangjie Duan, Yanfeng Bai, Xiaodong Teng, Jiayun Xu, Rong Fang, Suying Wang, Shan Zhong, Xiaotong Wang, Lisong Teng
    Modern Pathology.2024; 37(8): 100536.     CrossRef
  • Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
    Giovanni Maria Iannantuono, Silvia Riondino, Stefano Sganga, Mario Roselli, Francesco Torino
    International Journal of Molecular Sciences.2022; 23(7): 3995.     CrossRef
  • Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia
    Kiril Trpkov, Sean R. Williamson, Anthony J. Gill, Adebowale J. Adeniran, Abbas Agaimy, Reza Alaghehbandan, Mahul B. Amin, Pedram Argani, Ying-Bei Chen, Liang Cheng, Jonathan I. Epstein, John C. Cheville, Eva Comperat, Isabela Werneck da Cunha, Jennifer B
    Modern Pathology.2021; 34(6): 1167.     CrossRef
  • ESC, ALK, HOT and LOT: Three Letter Acronyms of Emerging Renal Entities Knocking on the Door of the WHO Classification
    Farshid Siadat, Kiril Trpkov
    Cancers.2020; 12(1): 168.     CrossRef
  • ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology
    Jen-Fan Hang, Hsiao-Jen Chung, Chin-Chen Pan
    Virchows Archiv.2020; 476(6): 921.     CrossRef
  • Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion
    Chang Gok Woo, Seok Jung Yun, Seung-Myoung Son, Young Hyun Lim, Ok-Jun Lee
    Yonsei Medical Journal.2020; 61(3): 262.     CrossRef
  • Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers
    Sean R. Williamson, Anthony J. Gill, Pedram Argani, Ying-Bei Chen, Lars Egevad, Glen Kristiansen, David J. Grignon, Ondrej Hes
    American Journal of Surgical Pathology.2020; 44(7): e47.     CrossRef
  • ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217
    Naoto Kuroda, Kiril Trpkov, Yuan Gao, Maria Tretiakova, Yajuan J. Liu, Monika Ulamec, Kengo Takeuchi, Abbas Agaimy, Christopher Przybycin, Cristina Magi-Galluzzi, Soichiro Fushimi, Fumiyoshi Kojima, Malthide Sibony, Jen-Fan Hang, Chin-Chen Pan, Asli Yilma
    Modern Pathology.2020; 33(12): 2564.     CrossRef
  • ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma
    Yiqi Zhu, Ning Liu, Wei Guo, Xiaohong Pu, Hongqian Guo, Weidong Gan, Dongmei Li
    Pathology - Research and Practice.2020; 216(12): 153286.     CrossRef
  • New and emerging renal entities: a perspective post‐WHO 2016 classification
    Kiril Trpkov, Ondřej Hes
    Histopathology.2019; 74(1): 31.     CrossRef
  • Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics
    Samer Nassif, Ziad M. El-Zaatari, Michel Attieh, Maya Hijazi, Najla Fakhreddin, Tarek Aridi, Fouad Boulos
    Medicine.2019; 98(32): e16702.     CrossRef
  • Targeted next-generation sequencing revealed distinct clinicopathologic and molecular features of VCL-ALK RCC: A unique case from an older patient without clinical evidence of sickle cell trait
    Xiao-tong Wang, Ru Fang, Sheng-bing Ye, Ru-song Zhang, Rui Li, Xuan Wang, Rong-hao Ji, Zhen-feng Lu, Heng-hui Ma, Xiao-jun Zhou, Qiu-yuan Xia, Qiu Rao
    Pathology - Research and Practice.2019; 215(11): 152651.     CrossRef
  • ALK-rearranged renal cell carcinomas in Polish population
    Adam Gorczynski, Piotr Czapiewski, Aleksandra Korwat, Lukasz Budynko, Monika Prelowska, Krzysztof Okon, Wojciech Biernat
    Pathology - Research and Practice.2019; 215(12): 152669.     CrossRef
  • ALK-TPM3 rearrangement in adult renal cell carcinoma: a case report and literature review
    Jing Yang, Lei Dong, Hong Du, Xiu-bo Li, Yan-xiao Liang, Guo-rong Liu
    Diagnostic Pathology.2019;[Epub]     CrossRef
  • Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach
    Reza Alaghehbandan, Delia Perez Montiel, Ana Silvia Luis, Ondrej Hes
    Cancers.2019; 12(1): 85.     CrossRef
  • ALK-TPM3 rearrangement in adult renal cell carcinoma: Report of a new case showing loss of chromosome 3 and literature review
    Yohan Bodokh, Damien Ambrosetti, Valérie Kubiniek, Branwel Tibi, Matthieu Durand, Jean Amiel, Morgane Pertuit, Anne Barlier, Florence Pedeutour
    Cancer Genetics.2018; 221: 31.     CrossRef
  • Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma
    Yong Jin Cho, Soo Hee Kim, Eun Kyung Kim, Jung Woo Han, Kyoo-Ho Shin, Hyuk Hu, Kyung Sik Kim, Young Deuk Choi, Sunghoon Kim, Young Han Lee, Jin-Suck Suh, Joong Bae Ahn, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha, Sung-Taek Jung, Hyo Song Kim
    BMC Cancer.2018;[Epub]     CrossRef
  • Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma
    Sumanta K. Pal, Paulo Bergerot, Nazli Dizman, Cristiane Bergerot, Jacob Adashek, Russell Madison, Jon H. Chung, Siraj M. Ali, Jeremy O. Jones, Ravi Salgia
    European Urology.2018; 74(1): 124.     CrossRef
  • Genetic analysis and clinicopathological features of ALK‐rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review
    Wenjuan Yu, Yuewei Wang, Yanxia Jiang, Wei Zhang, Yujun Li
    Histopathology.2017; 71(1): 53.     CrossRef
  • A case of anaplastic lymphoma kinase‐positive renal cell carcinoma coincident with Hodgkin lymphoma
    Yuzo Oyama, Haruto Nishida, Takahiro Kusaba, Hiroko Kadowaki, Motoki Arakane, Tsutomu Daa, Dai Watanabe, Yasuyuki Akita, Fuminori Sato, Hiromitsu Mimata, Shigeo Yokoyama
    Pathology International.2017; 67(12): 626.     CrossRef
  • Clinicopathologic and Molecular Pathology of Collecting Duct Carcinoma and Related Renal Cell Carcinomas
    An Na Seo, Ghilsuk Yoon, Jae Y. Ro
    Advances in Anatomic Pathology.2017; 24(2): 65.     CrossRef
  • The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications
    Soo Hee Kim, Woo Ick Yang, Yoo Hong Min, Young Hyeh Ko, Sun Och Yoon
    Tumor Biology.2016; 37(2): 2037.     CrossRef
  • New and emerging renal tumour entities
    Naoto Kuroda, Ondřej Hess, Ming Zhou
    Diagnostic Histopathology.2016; 22(2): 47.     CrossRef
  • ALK‐rearranged renal cell carcinomas in children
    Mariana M. Cajaiba, Lawrence J. Jennings, Stephen M. Rohan, Antonio R. Perez‐Atayde, Adrian Marino‐Enriquez, Jonathan A. Fletcher, James I. Geller, Katrin M. C. Leuer, Julia A. Bridge, Elizabeth J. Perlman
    Genes, Chromosomes and Cancer.2016; 55(5): 442.     CrossRef
  • Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene
    Hironori Kusano, Yuki Togashi, Jun Akiba, Fukuko Moriya, Katsuyoshi Baba, Naomi Matsuzaki, Yoshiaki Yuba, Yusuke Shiraishi, Hiroshi Kanamaru, Naoto Kuroda, Seiji Sakata, Kengo Takeuchi, Hirohisa Yano
    American Journal of Surgical Pathology.2016; 40(6): 761.     CrossRef
  • Expanding the spectrum of ALK‐rearranged renal cell carcinomas in children: Identification of a novel HOOK1‐ALK fusion transcript
    Mariana M. Cajaiba, Lawrence J. Jennings, David George, Elizabeth J. Perlman
    Genes, Chromosomes and Cancer.2016; 55(10): 814.     CrossRef
  • TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: Report of a case with a TPM3-ALK translocation
    Paul Scott Thorner, Mary Shago, Paula Marrano, Furqan Shaikh, Gino R. Somers
    Pathology - Research and Practice.2016; 212(10): 937.     CrossRef
  • ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult
    Marie Jeanneau, Valerie Gregoire, Claude Desplechain, Fabienne Escande, Dan Petre Tica, Sebastien Aubert, Xavier Leroy
    Pathology - Research and Practice.2016; 212(11): 1064.     CrossRef
Histologic Variations and Immunohistochemical Features of Metastatic Clear Cell Renal Cell Carcinoma
Cheol Lee, Jeong-Whan Park, Ja Hee Suh, Kyung Han Nam, Kyung Chul Moon
Korean J Pathol. 2013;47(5):426-432.   Published online October 25, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.5.426
  • 9,306 View
  • 77 Download
  • 17 Crossref
AbstractAbstract PDF
Background

Due to advancements in treatment of metastatic and advanced renal cell carcinoma (RCC), it has become increasingly important to diagnose metastatic RCC and the specific subtype. In this study, we investigated the diverse histologic features of metastatic clear cell renal cell carcinoma (CCRCC) cases in comparison with corresponding primary lesions.

Methods

We identified 119 metastatic CCRCC cases from 81 corresponding primary lesions diagnosed between 1995 and 2010 and evaluated the diverse histologic and immunohistochemical features of these lesions.

Results

A total of 44 primary lesions (54.3%) had a non-clear cell component in addition to a typical clear cell component. Of the 119 metastatic lesions, 63 lesions (52.9%) contained a non-clear cell component, and 29 metastatic lesions were composed of a non-clear cell component only. Rhabdoid features were the most frequent non-clear cell histology among the metastatic lesions. Metastatic CCRCCs mainly showed positive CD10 and epithelial membrane antigen staining and negative cytokeratin 7 staining.

Conclusions

Metastatic CCRCC commonly showed a variety of histologic features. If there is a difficulty to diagnose metastatic CCRCC due to a variety of histologic features or small biopsy specimen, histologic review of the primary lesion and immunohistochemical analysis can help determine the correct diagnosis.

Citations

Citations to this article as recorded by  
  • Sarcomatoid and Rhabdoid Renal Cell Carcinoma
    Adebowale J. Adeniran, Brian Shuch, Peter A. Humphrey
    American Journal of Surgical Pathology.2024; 48(7): e65.     CrossRef
  • Emerging Antibody-Drug Conjugate Therapies and Targets for Metastatic Renal Cell Carcinoma
    Harrison C. Gottlich, Reza Nabavizadeh, Mihai Dumbrava, Rodrigo Rodrigues Pessoa, Ahmed M. Mahmoud, Ishita Garg, Jacob Orme, Brian A. Costello, John Cheville, Fabrice Lucien
    Kidney Cancer.2023; 7(1): 161.     CrossRef
  • Painful, bleeding fingertip papule
    Jane Gay, Sarah Simpson, Patrick Rush, Alex Holliday
    JAAD Case Reports.2022; 21: 130.     CrossRef
  • Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma
    Rory M. Bade, Jennifer L. Schehr, Hamid Emamekhoo, Benjamin K. Gibbs, Tamara S. Rodems, Matthew C. Mannino, Joshua A. Desotelle, Erika Heninger, Charlotte N. Stahlfeld, Jamie M. Sperger, Anupama Singh, Serena K. Wolfe, David J. Niles, Waddah Arafat, John
    Molecular Oncology.2021; 15(9): 2330.     CrossRef
  • Laparoscopic cytoreductive nephrectomy and adrenalectomy for metachronous RCC metastases—Case report
    Bogdan Petrut, Cristina Eliza Bujoreanu, Vasile Vlad Hardo, Adrian Barbos, Bogdan Fetica
    International Journal of Surgery Case Reports.2020; 74: 268.     CrossRef
  • Does CARMENA mark the end of cytoreductive nephrectomy for metastatic renal cell carcinoma?
    Steven L. Chang, Toni K. Choueiri, Lauren C. Harshman
    Urologic Oncology: Seminars and Original Investigations.2019; 37(8): 525.     CrossRef
  • Metastatic TFE3-overexpressing renal clear cell carcinoma with dense granules: a histological, immunohistochemical, and ultrastructural study
    Shoujun Chen, Elba A. Turbat-Herrera, Guillermo A. Herrera, Meghna Chadha, Rodney E. Shackelford, Eric X. Wei
    Ultrastructural Pathology.2018; 42(4): 369.     CrossRef
  • The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
    Rana R. McKay, Dominick Bossé, Wanling Xie, Stephanie A.M. Wankowicz, Abdallah Flaifel, Raphael Brandao, Aly-Khan A. Lalani, Dylan J. Martini, Xiao X. Wei, David A. Braun, Eliezer Van Allen, Daniel Castellano, Guillermo De Velasco, J. Connor Wells, Daniel
    Cancer Immunology Research.2018; 6(7): 758.     CrossRef
  • Implication of PHF2 Expression in Clear Cell Renal Cell Carcinoma
    Cheol Lee, Bohyun Kim, Boram Song, Kyung Chul Moon
    Journal of Pathology and Translational Medicine.2017; 51(4): 359.     CrossRef
  • Pulmonary metastasectomy from renal cell carcinoma including 3 cases with sarcomatoid component
    Tsuyoshi Ueno, Motohiro Yamashita, Shigeki Sawada, Ryujiro Sugimoto, Noriko Nishijima, Yoshifumi Sugawara, Iku Ninomiya
    General Thoracic and Cardiovascular Surgery.2016; 64(3): 149.     CrossRef
  • Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?
    Aleksandra Semeniuk-Wojtaś, Rafał Stec, Cezary Szczylik
    Urologic Oncology: Seminars and Original Investigations.2016; 34(5): 215.     CrossRef
  • Concordance of Pathologic Features Between Metastatic Sites and the Primary Tumor in Surgically Resected Metastatic Renal Cell Carcinoma
    Sarah P. Psutka, John C. Cheville, Brian A. Costello, Suzanne B. Stewart-Merrill, Christine M. Lohse, Bradley C. Leibovich, Stephen A. Boorjian, R. Houston Thompson
    Urology.2016; 96: 106.     CrossRef
  • The Correlation of Tissue-Based Biomarkers in Primary and Metastatic Renal Cell Carcinoma Lesions: A Tissue Microarray Study
    Sung Han Kim, Weon Seo Park, Eun Young Park, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
    The Korean Journal of Urological Oncology.2016; 14(3): 152.     CrossRef
  • Long-term follow-up and clinical course of a rare case of von Hippel-Lindau disease: A case report and review of the literature
    YU ZOU, JINGJING XU, MINMING ZHANG
    Oncology Letters.2016; 11(5): 3273.     CrossRef
  • Genetic alterations in renal cell carcinoma with rhabdoid differentiation
    Carmen M. Perrino, Vishwanathan Hucthagowder, Michael Evenson, Shashikant Kulkarni, Peter A. Humphrey
    Human Pathology.2015; 46(1): 9.     CrossRef
  • High expression of APRIL correlates with poor prognosis in clear cell renal cell carcinoma
    Cheol Lee, Jeong-Whan Park, Ja Hee Suh, Kyung Chul Moon
    Pathology - Research and Practice.2015; 211(11): 824.     CrossRef
  • A Case of Cutaneous Metastasis from a Clear Cell Renal Cell Carcinoma with an Eosinophilic Cell Component to the Submandibular Region
    Yusuke Amano, Sumie Ohni, Toshiyuki Ishige, Taku Homma, Tsutomu Yamada, Nobuyuki Nishimori, Norimichi Nemoto
    Journal of Nihon University Medical Association.2015; 74(2): 73.     CrossRef
Clear Cell Papillary Renal Cell Carcinoma: A Report of 15 Cases Including Three Cases of Concurrent Other-Type Renal Cell Carcinomas
Jeong Hwan Park, Cheol Lee, Ja Hee Suh, Kyung Chul Moon
Korean J Pathol. 2012;46(6):541-547.   Published online December 26, 2012
DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.6.541
  • 7,500 View
  • 61 Download
  • 23 Crossref
AbstractAbstract PDF
Background

Clear cell papillary renal cell carcinoma (CCPRCC) is a recently established subtype of renal epithelial tumor. The aim of this study was to identify the diagnostic criteria of CCPRCC with an emphasis on immunohistochemical studies, and to report three cases with concurrent other-type renal cell carcinoma (RCC).

Methods

A total of 515 RCC patients that consecutively underwent surgical resection at Seoul National University Hospital from 1 January 2010 to 31 December 2011 were screened. Each case was reviewed based on the histologic features and was evaluated immunohistochemically.

Results

A total of 15 CCPRCCs were identified, which composed 2.9% of the total RCCs. The mean age was 52 years, and the average tumor size was 1.65 cm. All 15 cases showed low nuclear grade, no lymph node metastasis and no distant metastasis. The CCPRCCs showed variable architectural patterns including cystic, trabecular, papillary, and acinar. All of the cases showed moderate to intense immunoreactivity for cytokeratin 7 (CK7). CD10 was negative or showed focal weak positivity. Three cases had concurrent other-type RCC, including a clear cell RCC and an acquired cystic disease-associated RCC.

Conclusions

The strong CK7 and negative or focal weak CD10 expression will be useful for the diagnosis of CCPRCC.

Citations

Citations to this article as recorded by  
  • Vascular, adipose tissue, and/or calyceal invasion in clear cell tubulopapillary renal cell tumour: potentially problematic diagnostic scenarios
    Ankur R Sangoi, Harrison Tsai, Lara Harik, Jonathan Mahlow, Maria Tretiakova, Sean R Williamson, Michelle S Hirsch
    Histopathology.2024; 84(7): 1167.     CrossRef
  • Clinical features and Surgical Outcome of Clear Cell Papillary Renal Cell Tumor: result from a prospective cohort
    Si Hyun Kim, Jang Hee Han, Seung-hwan Jeong, Hyeong Dong Yuk, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Kyung Chul Moon, Chang Wook Jeong
    BMC Urology.2023;[Epub]     CrossRef
  • Coexistence of multiple clear cell papillary renal cell carcinoma with renal oncocytoma: a case report
    Amine Hermi, Ahmed Saadi, Seif Mokadem, Ahlem Blel, Marouene Chakroun, Mohamed Riadh Ben Slama
    Annals of Medicine & Surgery.2023; 85(5): 2017.     CrossRef
  • Renal Cell Carcinoma in End-Stage Renal Disease: A Review and Update
    Ziad M. El-Zaatari, Luan D. Truong
    Biomedicines.2022; 10(3): 657.     CrossRef
  • The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management
    Stanley Weng, Renzo G. DiNatale, Andrew Silagy, Roy Mano, Kyrollis Attalla, Mahyar Kashani, Kate Weiss, Nicole E. Benfante, Andrew G. Winer, Jonathan A. Coleman, Victor E. Reuter, Paul Russo, Ed Reznik, Satish K. Tickoo, A. Ari Hakimi
    European Urology.2021; 79(4): 468.     CrossRef
  • Clear cell papillary renal cell carcinoma: Characteristics and survival outcomes from a large single institutional series
    James E. Steward, Sean Q. Kern, Liang Cheng, Ronald S. Boris, Yan Tong, Clint D. Bahler, Timothy A. Masterson, K. Clint Cary, Hristos Kaimakliotis, Thomas Gardner, Chandru P. Sundaram
    Urologic Oncology: Seminars and Original Investigations.2021; 39(6): 370.e21.     CrossRef
  • Clear cell papillary renal cell carcinoma: an update after 15 years
    Sean R. Williamson
    Pathology.2021; 53(1): 109.     CrossRef
  • Clear Cell Papillary Renal Cell Carcinoma
    Jianping Zhao, Eduardo Eyzaguirre
    Archives of Pathology & Laboratory Medicine.2019; 143(9): 1154.     CrossRef
  • Clear cell papillary renal cell carcinoma – An indolent subtype of renal tumor
    Wei-Jen Chen, Chin-Chen Pan, Shu-Huei Shen, Hsiao-Jen Chung, Chih-Chieh Lin, Alex T.L. Lin, Yen-Hwa Chang
    Journal of the Chinese Medical Association.2018; 81(10): 878.     CrossRef
  • Clear cell papillary renal cell carcinoma: A case report and review of the literature
    Sung Han Kim, Whi-An Kwon, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
    World Journal of Nephrology.2018; 7(8): 155.     CrossRef
  • Clinical features and survival analysis of clear cell papillary renal cell carcinoma: A 10‑year retrospective study from two institutions
    Yiqiu Wang, Ying Ding, Jian Wang, Min Gu, Zengjun Wang, Chao Qin, Conghui Han, Hongxia Li, Xia Liu, Pengfei Wu, Guangchao Li
    Oncology Letters.2018;[Epub]     CrossRef
  • A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: A report based on 624 consecutive tumors from a single tertiary center
    Maria Rosaria Raspollini, Ilaria Montagnani, Rodolfo Montironi, Liang Cheng, Guido Martignoni, Andrea Minervini, Sergio Serni, Giulio Nicita, Marco Carini, Antonio Lopez-Beltran
    Pathology - Research and Practice.2017; 213(7): 804.     CrossRef
  • Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma
    Hari P. Dhakal, Jesse K. McKenney, Li Yan Khor, Jordan P. Reynolds, Cristina Magi-Galluzzi, Christopher G. Przybycin
    American Journal of Surgical Pathology.2016; 40(2): 141.     CrossRef
  • New and emerging renal tumour entities
    Naoto Kuroda, Ondřej Hess, Ming Zhou
    Diagnostic Histopathology.2016; 22(2): 47.     CrossRef
  • Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features
    Hanan AlSaeid Alshenawy
    Pathology & Oncology Research.2015; 21(4): 893.     CrossRef
  • Immunohistochemical panel for differentiating renal cell carcinoma with clear and papillary features
    Hanan AlSaeid Alshenawy
    Journal of Microscopy and Ultrastructure.2015; 3(2): 68.     CrossRef
  • Clear Cell-Papillary Renal Cell Carcinoma of the Kidney Not Associated With End-stage Renal Disease
    Manju Aron, Elena Chang, Loren Herrera, Ondrej Hes, Michelle S. Hirsch, Eva Comperat, Philippe Camparo, Priya Rao, Maria Picken, Michal Michal, Rodolfo Montironi, Pheroze Tamboli, Federico Monzon, Mahul B. Amin
    American Journal of Surgical Pathology.2015; 39(7): 873.     CrossRef
  • Papillary or pseudopapillary tumors of the kidney
    Fang-Ming Deng, Max X. Kong, Ming Zhou
    Seminars in Diagnostic Pathology.2015; 32(2): 124.     CrossRef
  • Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?
    Mairo L. Diolombi, Liang Cheng, Pedram Argani, Jonathan I. Epstein
    American Journal of Surgical Pathology.2015; 39(12): 1621.     CrossRef
  • Targeted next‐generation sequencing and non‐coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes
    Charles H Lawrie, Erika Larrea, Gorka Larrinaga, Ibai Goicoechea, María Arestin, Marta Fernandez‐Mercado, Ondrej Hes, Francisco Cáceres, Lorea Manterola, José I López
    The Journal of Pathology.2014; 232(1): 32.     CrossRef
  • Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma
    Haijun Zhou, Shaojiang Zheng, Luan D. Truong, Jae Y. Ro, Alberto G. Ayala, Steven S. Shen
    Human Pathology.2014; 45(1): 59.     CrossRef
  • Clear cell papillary renal cell carcinoma: Incidence, morphological features, immunohistochemical profile, and biologic behavior: A single institution study
    Borislav A. Alexiev, Cinthia B. Drachenberg
    Pathology - Research and Practice.2014; 210(4): 234.     CrossRef
  • MRI Phenotype in Renal Cancer
    Naomi Campbell, Andrew B. Rosenkrantz, Ivan Pedrosa
    Topics in Magnetic Resonance Imaging.2014; 23(2): 95.     CrossRef
ERG Immunohistochemistry and Clinicopathologic Characteristics in Korean Prostate Adenocarcinoma Patients
Ja Hee Suh, Jeong-Whan Park, Cheol Lee, Kyung Chul Moon
Korean J Pathol. 2012;46(5):423-428.   Published online October 25, 2012
DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.5.423
  • 7,970 View
  • 43 Download
  • 18 Crossref
AbstractAbstract PDF
Background

Transmembrane protease serine 2-ETS related gene (TMPRSS2-ERG) gene fusion, the most common genetic alternation in prostate cancer, is associated with protein expression of the oncogene ERG. Recently, an immunohistochemical staining method using an anti-ERG antibody was shown to have a strong correlation with altered ERG protein expression.

Methods

We analyzed a total of 303 radical prostatectomy specimens (obtained from Korean prostate cancer cases) using a constructed tissue microarray and ERG immunohistochemical staining. Thereafter, we evaluated the association between ERG expression and clinicopathological factors.

Results

The ERG-positive rate was 24.4% (74/303) and significantly higher ERG expression was observed in the subgroup with a lower Gleason score (p=0.004). Analysis of the histologic pattern of prostate adenocarcinomas revealed that tumors with discrete glandular units (Gleason pattern 3) displayed higher frequency of ERG expression (p=0.016). The ERG-positive rate was lower than that found (approximately 50%) in studies involving western populations. Other factors including age, tumor volume, initial protein-specific antigen level, a pathological stage and margin status were not significantly related with the ERG expression.

Conclusions

ERG immunohistochemical staining is significantly higher in tumors with well-formed glands and is associated with a lower Gleason score.

Citations

Citations to this article as recorded by  
  • A cross-sectional study of ERG expression and the relationship with clinicopathological features of Prostate cancer in Southwestern Uganda
    Yekosani Mitala, Brian Ssenkumba, Abraham Birungi, Ritah Kiconco, Marvin Mwesigwa Mutakooha, Raymond Atwine
    Diagnostic Pathology.2024;[Epub]     CrossRef
  • The relevance of ERG immunoexpression intensity for prostatic adenocarcinoma in radical prostatectomy of 635 samples
    Priscilla Mariana Freitas Aguiar Feitosa, Carlos Gustavo Hirth, Isabelle Joyce De Lima Silva‐Fernandes, Conceição Aparecida Dornelas
    APMIS.2023; 131(9): 465.     CrossRef
  • Application and Pitfalls of Immunohistochemistry in Diagnosis of Challenging Genitourinary Cases
    Jenny Ross, Guangyuan Li, Ximing J. Yang
    Archives of Pathology & Laboratory Medicine.2020; 144(3): 290.     CrossRef
  • ERG expression in prostate cancer: diagnostic significance and histopathological correlations
    ManarA Abdel-Rahman, HanyO Habashy
    Egyptian Journal of Pathology.2020; 40(2): 212.     CrossRef
  • The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center
    Ling Nie, Xiuyi Pan, Mengni Zhang, Xiaoxue Yin, Jing Gong, Xueqin Chen, Miao Xu, Qiao Zhou, Ni Chen
    The Prostate.2019; 79(8): 819.     CrossRef
  • MiR-1271 Inhibits Cell Growth in Prostate Cancer by Targeting ERG
    Miao Wang, Wei Gao, Dehong Lu, Lianghong Teng
    Pathology & Oncology Research.2018; 24(2): 385.     CrossRef
  • Ethnicity and ERG frequency in prostate cancer
    Jason Sedarsky, Michael Degon, Shiv Srivastava, Albert Dobi
    Nature Reviews Urology.2018; 15(2): 125.     CrossRef
  • The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature
    Arie Carneiro, Álan Roger Gomes Barbosa, Lucas Seiti Takemura, Paulo Priante Kayano, Natasha Kouvaleski Saviano Moran, Carolina Ko Chen, Marcelo Langer Wroclawski, Gustavo Caserta Lemos, Isabela Werneck da Cunha, Marcos Takeo Obara, Marcos Tobias-Machado,
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • Prognostic implications of ERG, PTEN, and fatty acid synthase expression in localized prostate cancer
    Anan Fathi, Naglaa A. Mostafa, Nabila Hefzi, Khaled A. Mansour
    Egyptian Journal of Pathology.2018; 38(1): 162.     CrossRef
  • Intrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer
    Ja Hee Suh, Jeong Hwan Park, Cheol Lee, Kyung Chul Moon
    The Prostate.2017; 77(14): 1438.     CrossRef
  • Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors
    Se Un Jeong, Anuja Kashikar Kekatpure, Ja-Min Park, Minkyu Han, Hee Sang Hwang, Hui Jeong Jeong, Heounjeong Go, Yong Mee Cho
    Journal of Pathology and Translational Medicine.2017; 51(5): 471.     CrossRef
  • Correlation of ERG immunohistochemistry with molecular detection ofTMPRSS2-ERGgene fusion
    Ji-Youn Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, So Young Kang, Yoon-La Choi, Ghee Young Kwon
    Journal of Clinical Pathology.2016; 69(7): 586.     CrossRef
  • Prostate Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG
    Maria P. Silva, João D. Barros-Silva, Elin Ersvær, Wanja Kildal, Tarjei Sveinsgjerd Hveem, Manohar Pradhan, Joana Vieira, Manuel R. Teixeira, Håvard E. Danielsen
    Translational Oncology.2016; 9(6): 575.     CrossRef
  • Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer
    Sung Han Kim, Soo Hee Kim, Jae Young Joung, Geon Kook Lee, Eun Kyung Hong, Kyung Min Kang, Ami Yu, Byung Ho Nam, Jinsoo Chung, Ho Kyung Seo, Weon Seo Park, Kang Hyun Lee, Rui Medeiros
    PLOS ONE.2015; 10(4): e0122498.     CrossRef
  • ERG oncoprotein expression in prostate carcinoma patients of different ethnicities
    GREGORY M. KELLY, YINK HEAY KONG, ALBERT DOBI, SHIV SRIVASTAVA, ISABELL A. SESTERHENN, RAJADURAI PATHMANATHAN, HUI MENG TAN, SHYH-HAN TAN, SOK CHING CHEONG
    Molecular and Clinical Oncology.2015; 3(1): 23.     CrossRef
  • ERG positive prostatic cancer may show a more angiogenetic phenotype
    Aleksandra Strzępek, Karolina Kaczmarczyk, Magdalena Białas, Joanna Szpor, Grzegorz Dyduch, Tomasz Szopiński, Piotr Chłosta, Krzysztof Okoń
    Pathology - Research and Practice.2014; 210(12): 897.     CrossRef
  • Recurrent Gene Fusions in Prostate Cancer: Their Clinical Implications and Uses
    Daphne Hessels, Jack A. Schalken
    Current Urology Reports.2013; 14(3): 214.     CrossRef
  • ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients
    Esther Baena, Zhen Shao, Douglas E. Linn, Kimberly Glass, Melanie J. Hamblen, Yuko Fujiwara, Jonghwan Kim, Minh Nguyen, Xin Zhang, Frank J. Godinho, Roderick T. Bronson, Lorelei A. Mucci, Massimo Loda, Guo-Cheng Yuan, Stuart H. Orkin, Zhe Li
    Genes & Development.2013; 27(6): 683.     CrossRef
Cyclooxygenase-2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma
Ji Won Lee, Jeong Hwan Park, Ja Hee Suh, Kyung Han Nam, Ji-Young Choe, Hae Yoen Jung, Ji Yoen Chae, Kyung Chul Moon
Korean J Pathol. 2012;46(3):237-245.   Published online June 22, 2012
DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.3.237
  • 7,743 View
  • 48 Download
  • 16 Crossref
AbstractAbstract PDF
Background

The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines.

Methods

Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines.

Results

Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity.

Conclusions

This study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC.

Citations

Citations to this article as recorded by  
  • Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition
    Xiao-Jun Li, Ping Suo, Yan-Ni Wang, Liang Zou, Xiao-Li Nie, Ying-Yong Zhao, Hua Miao
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • The tumor microenvironment and immune targeting therapy in pediatric renal tumors
    Amy B. Hont, Benoit Dumont, Kathryn S. Sutton, John Anderson, Alex Kentsis, Jarno Drost, Andrew L. Hong, Arnauld Verschuur
    Pediatric Blood & Cancer.2023;[Epub]     CrossRef
  • Free-fatty acid receptor-1 (FFA1/GPR40) promotes papillary RCC proliferation and tumor growth via Src/PI3K/AKT/NF-κB but suppresses migration by inhibition of EGFR, ERK1/2, STAT3 and EMT
    Priyanka F. Karmokar, Nader H. Moniri
    Cancer Cell International.2023;[Epub]     CrossRef
  • Flavonoids derived from Anemarrhenae Rhizoma ameliorate inflammation of benign prostatic hyperplasia via modulating COX/LOX pathways
    Xiaotong Cao, Ying Shang, Weigui Kong, Shuqing Jiang, Jun Liao, Ronghua Dai
    Journal of Ethnopharmacology.2022; 284: 114740.     CrossRef
  • Kirenol, darutoside and hesperidin contribute to the anti-inflammatory and analgesic activities of Siegesbeckia pubescens makino by inhibiting COX-2 expression and inflammatory cell infiltration
    Yu-Sang Li, Jian Zhang, Gui-Hua Tian, Hong-Cai Shang, He-Bin Tang
    Journal of Ethnopharmacology.2021; 268: 113547.     CrossRef
  • Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors
    Jefferson da Rocha Tenório, Leorik Pereira da Silva, Marília Gabriela de Aguiar Xavier, Thalita Santana, George João Ferreira do Nascimento, Ana Paula Veras Sobral
    European Archives of Oto-Rhino-Laryngology.2018; 275(9): 2341.     CrossRef
  • Retrospective evaluation ofCOX‐2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy
    S. Carvalho, A. L. Stoll, S. L. Priestnall, A. Suarez‐Bonnet, K. Rassnick, S. Lynch, I. Schoepper, G. Romanelli, P. Buracco, M. Atherton, E. M. de Merlo, A. Lara‐Garcia
    Veterinary and Comparative Oncology.2017; 15(4): 1280.     CrossRef
  • Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
    Arancha Cebrián, Teresa Gómez del Pulgar, María José Méndez-Vidal, María Luisa Gonzálvez, Nuria Lainez, Daniel Castellano, Iciar García-Carbonero, Emilio Esteban, Maria Isabel Sáez, Rosa Villatoro, Cristina Suárez, Alfredo Carrato, Javier Munárriz-Ferránd
    Scientific Reports.2017;[Epub]     CrossRef
  • COX-2 expression in ovarian cancer: an updated meta-analysis
    Haiming Sun, Xuelong Zhang, Donglin Sun, Xueyuan Jia, Lidan Xu, Yuandong Qiao, Yan Jin
    Oncotarget.2017; 8(50): 88152.     CrossRef
  • COX-2 Expression in Renal Cell Carcinoma and Correlations with Tumor Grade, Stage and Patient Prognosis
    Hedieh Moradi Tabriz, Marzieh Mirzaalizadeh, Shahram Gooran, Farzaneh Niki, Maryam Jabri
    Asian Pacific Journal of Cancer Prevention.2016; 17(2): 535.     CrossRef
  • Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma
    Kosuke Saito, Eri Arai, Keiko Maekawa, Masaki Ishikawa, Hiroyuki Fujimoto, Ryo Taguchi, Kenji Matsumoto, Yae Kanai, Yoshiro Saito
    Scientific Reports.2016;[Epub]     CrossRef
  • Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma
    Łukasz Kuźbicki, Dariusz Lange, Agata Stanek-Widera, Barbara W. Chwirot
    Melanoma Research.2016; 26(5): 448.     CrossRef
  • New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis
    Honor J. Hugo, C. Saunders, R. G. Ramsay, E. W. Thompson
    Journal of Mammary Gland Biology and Neoplasia.2015; 20(3-4): 109.     CrossRef
  • The Role of Prostaglandin E2 in Renal Cell Cancer Development: Future Implications for Prognosis and Therapy
    Katarzyna Kaminska, Cezary Szczylik, Fei Lian, Anna M Czarnecka
    Future Oncology.2014; 10(14): 2177.     CrossRef
  • Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications
    Małgorzata Rydzanicz, Tomasz Wrzesiński, Hans A.R. Bluyssen, Joanna Wesoły
    Cancer Letters.2013; 341(2): 111.     CrossRef
  • Quantitative Assessment of the Association of COX-2 (Cyclooxygenase-2) Immunoexpression with Prognosis in Human Osteosarcoma: A Meta-Analysis
    Zhe Wang, Maolin He, Zengming Xiao, Hao Wu, Yang Wu, Dominique Heymann
    PLoS ONE.2013; 8(12): e82907.     CrossRef
Practical Standardization in Renal Biopsy Reporting.
So Young Jin, Hyeon Joo Jeong, Sun Hee Sung, Beom Jin Lim, Jee Young Han, Soon Won Hong, Hyun Ee Yim, Yeong Jin Choi, Yong Mee Cho, Myoung Jae Kang, Kyung Chul Moon, Hee Jeong Cha, Seung Yeon Ha, Mi Seon Kang, Mee Young So, Kwang Sun Suh, Jong Eun Joo, Yong Jin Kim, Nam Hee Won, Moon Hyang Park
Korean J Pathol. 2010;44(6):613-622.
DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.6.613
  • 4,433 View
  • 157 Download
  • 2 Crossref
AbstractAbstract PDF
BACKGROUND
To standardize renal biopsy reporting and diagnosis, The Renal Pathology Study Group of the Korean Society of Pathologists (RPSKSP) has developed a renal pathology reporting format for the native and allograft kidney.
METHODS
A consensus checklist of a provisional renal biopsy format was sent to all members of the RPSKSP. Feed back opinions regarding the practical application of the checklist to the diagnostic work were received.
RESULTS
Kidney biopsies require three essential examinations: by light microscopy, immunofluorescence (IF), and electron microscopy (EM). A final report of a renal biopsy should include information on specimen adequacy and a description of the morphologic change using a systematic semiquantitative method for each of the compartments, with optional separate IF and EM reports.
CONCLUSIONS
A standard renal biopsy report format is important in establishing clinicopathologic correlations, making reliable prognostic considerations, comparing the findings in sequential biopsies and evaluating the effects of therapy.

Citations

Citations to this article as recorded by  
  • Additional antihypertensive effect of magnesium supplementation with an angiotensin II receptor blocker in hypomagnesemic rats
    Kyubok Jin, Tae Hee Kim, Yeong Hoon Kim, Yang Wook Kim
    The Korean Journal of Internal Medicine.2013; 28(2): 197.     CrossRef
  • Clinicopathologic Features of IgA-Dominant Postinfectious Glomerulonephritis
    Tai Yeon Koo, Gheun-Ho Kim, Hyang Park
    Korean Journal of Pathology.2012; 46(2): 105.     CrossRef
The Prognostic Implications of Cystic Change in Clear Cell Renal Cell Carcinoma.
Heae Surng Park, Eun Jung Jung, Jae Kyung Myung, Kyung Chul Moon
Korean J Pathol. 2010;44(2):149-154.
DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.2.149
  • 4,991 View
  • 83 Download
  • 4 Crossref
AbstractAbstract PDF
BACKGROUND
Cystic renal cell carcinoma has been reported to have a good prognosis. However, previous studies included cases of multilocular cystic renal cell carcinoma, which has an excellent prognosis, and renal cell carcinoma with cystic necrosis, which has an adverse prognosis. Therefore, we analyzed the prognostic influence of cystic change in clear cell renal cell carcinoma after excluding those morphological features.
METHODS
We identified 225 patients with clear cell renal cell carcinoma who underwent nephrectomy between 2001 and 2003. The clinicopathologic features were compared with clinical outcomes.
RESULTS
Cystic change in clear cell renal cell carcinoma (n = 66) was significantly associated with younger patient age (< 55), smaller tumor size (< or = 4 cm), lower pT stage (pT1, T2), M0 stage at initial diagnosis, lower tumor, node, and metastasis stage (I, II), and lower nuclear grade (1, 2). Patients with cystic change in clear cell renal cell carcinoma had significantly longer cancer-specific (p = 0.015) and progression-free survival (p = 0.004) than those without cystic change, by univariate analysis. Multivariate analysis revealed that cystic change significantly decreased the risk of cancer progression (risk ratio, 0.27; 95% confidence interval, 0.11 to 0.69).
CONCLUSIONS
In patients with clear cell renal cell carcinoma, cystic change is a good independent predictor for survival.

Citations

Citations to this article as recorded by  
  • Update on MRI of Cystic Renal Masses Including Bosniak Version 2019
    Satheesh Krishna, Nicola Schieda, Ivan Pedrosa, Nicole Hindman, Ronaldo H. Baroni, Stuart G. Silverman, Matthew S. Davenport
    Journal of Magnetic Resonance Imaging.2021; 54(2): 341.     CrossRef
  • Klotho plays a critical role in clear cell renal cell carcinoma progression and clinical outcome
    Ji-Hee Kim, Kyu-Hee Hwang, Sayamaa Lkhagvadorj, Jae Hung Jung, Hyun Chul Chung, Kyu-Sang Park, In Deok Kong, Minseob Eom, Seung-Kuy Cha
    The Korean Journal of Physiology & Pharmacology.2016; 20(3): 297.     CrossRef
  • Insulin Receptor Expression in Clear Cell Renal Cell Carcinoma and Its Relation to Prognosis
    Sayamaa Lkhagvadorj, Sung Soo Oh, Mi-Ra Lee, Jae Hung Jung, Hyun Chul Chung, Seung-Kuy Cha, Minseob Eom
    Yonsei Medical Journal.2014; 55(4): 861.     CrossRef
  • Determination of the Cutoff Value of the Proportion of Cystic Change for Prognostic Stratification of Clear Cell Renal Cell Carcinoma
    Heae Surng Park, Kyoungbun Lee, Kyung Chul Moon
    Journal of Urology.2011; 186(2): 423.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine
TOP